Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
Palli SR, et al. Among authors: chastek b.
J Manag Care Spec Pharm. 2021 Jul;27(7):810-824. doi: 10.18553/jmcp.2021.20514. Epub 2021 Mar 25.
J Manag Care Spec Pharm. 2021.
PMID: 33764161
Free PMC article.
OBJECTIVE: To compare chronic obstructive pulmonary disease (COPD)-related and all-cause health care resource utilization (HCRU) and costs between COPD patients initiating tiotropium (TIO) + olodaterol (OLO) versus (a) other LAMA + LABA FDCs and (b) umeclidinium (UMEC) + v …
OBJECTIVE: To compare chronic obstructive pulmonary disease (COPD)-related and all-cause health care resource utilization (HCRU) and costs b …